APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Neisseria meningitidis Infections Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Neisseria meningitidis Infections Drug Market Outlook and Growth Opportunities 2026

Report ID 174016250419 December 2025193 pages

Choose your research edition.

Industry ResearchNeisseria meningitidis Infections Drug Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Neisseria meningitidis Infections Drug Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Neisseria meningitidis Infections Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neisseria meningitidis Infections Drug Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Neisseria meningitidis Infections Drug Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Neisseria meningitidis Infections Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Neisseria meningitidis Infections Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neisseria meningitidis Infections Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neisseria meningitidis Infections Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Neisseria meningitidis Infections Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Neisseria meningitidis Infections Drug market include Biological E Ltd, Griffith University, ImmunoBiology Ltd, JN-International Medical Corp, MGB Biopharma Ltd, Panacea Biotec Ltd, Sanofi Pasteur SA, Serum Institute of India Ltd and Wellstat Vaccines LLC, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Neisseria meningitidis Infections Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neisseria meningitidis Infections Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neisseria meningitidis Infections Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Neisseria meningitidis Infections Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Neisseria meningitidis Infections Drug Segment by Company

Biological E Ltd

Griffith University

ImmunoBiology Ltd

JN-International Medical Corp

MGB Biopharma Ltd

Panacea Biotec Ltd

Sanofi Pasteur SA

Serum Institute of India Ltd

Wellstat Vaccines LLC

Beijing Minhai Biotechnology Co Ltd

GlaxoSmithKline Plc

China National Pharmaceutical Group Corp

Pfizer Inc

Neisseria meningitidis Infections Drug Segment by Type

TP-10

NCL-195

MGBBP-3

Others

Neisseria meningitidis Infections Drug Segment by Application

Hospital

Clinic

Others

Neisseria meningitidis Infections Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Neisseria meningitidis Infections Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Neisseria meningitidis Infections Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Neisseria meningitidis Infections Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Neisseria meningitidis Infections Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neisseria meningitidis Infections Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neisseria meningitidis Infections Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neisseria meningitidis Infections Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Neisseria meningitidis Infections Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neisseria meningitidis Infections Drug industry.

Chapter 3: Detailed analysis of Neisseria meningitidis Infections Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Neisseria meningitidis Infections Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Neisseria meningitidis Infections Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Neisseria meningitidis Infections Drug Industry Trends Table 2. Neisseria meningitidis Infections Drug Industry Drivers Table 3. Neisseria meningitidis Infections Drug Industry Opportunities and Challenges Table 4. Neisseria meningitidis Infections Drug Industry Restraints Table 5. Global Neisseria meningitidis Infections Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Neisseria meningitidis Infections Drug Revenue Share by Company (2021-2026) Table 7. Global Neisseria meningitidis Infections Drug Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Neisseria meningitidis Infections Drug Sales Volume Share by Company (2021-2026) Table 9. Global Neisseria meningitidis Infections Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Neisseria meningitidis Infections Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Neisseria meningitidis Infections Drug Key Company Manufacturing Base & Headquarters Table 12. Global Neisseria meningitidis Infections Drug Company, Product Type & Application Table 13. Global Neisseria meningitidis Infections Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Neisseria meningitidis Infections Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of TP-10 Table 18. Significant Companies of NCL-195 Table 19. Significant Companies of MGBBP-3 Table 20. Significant Companies of Others Table 21. Global Neisseria meningitidis Infections Drug Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 22. Global Neisseria meningitidis Infections Drug Sales Volume by Type (2021-2026) & (W Units) Table 23. Global Neisseria meningitidis Infections Drug Sales Volume by Type (2027-2032) & (W Units) Table 24. Global Neisseria meningitidis Infections Drug Sales Volume Share by Type (2021-2026) Table 25. Global Neisseria meningitidis Infections Drug Sales Volume Share by Type (2027-2032) Table 26. Global Neisseria meningitidis Infections Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Neisseria meningitidis Infections Drug Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Neisseria meningitidis Infections Drug Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Neisseria meningitidis Infections Drug Sales Value Share by Type (2021-2026) Table 30. Global Neisseria meningitidis Infections Drug Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospital Table 32. Significant Companies of Clinic Table 33. Significant Companies of Others Table 34. Global Neisseria meningitidis Infections Drug Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 35. Global Neisseria meningitidis Infections Drug Sales Volume by Application (2021-2026) & (W Units) Table 36. Global Neisseria meningitidis Infections Drug Sales Volume by Application (2027-2032) & (W Units) Table 37. Global Neisseria meningitidis Infections Drug Sales Volume Share by Application (2021-2026) Table 38. Global Neisseria meningitidis Infections Drug Sales Volume Share by Application (2027-2032) Table 39. Global Neisseria meningitidis Infections Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Neisseria meningitidis Infections Drug Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Neisseria meningitidis Infections Drug Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Neisseria meningitidis Infections Drug Sales Value Share by Application (2021-2026) Table 43. Global Neisseria meningitidis Infections Drug Sales Value Share by Application (2027-2032) Table 44. Global Neisseria meningitidis Infections Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 45. Global Neisseria meningitidis Infections Drug Sales by Region (2021-2026) & (W Units) Table 46. Global Neisseria meningitidis Infections Drug Sales Market Share by Region (2021-2026) Table 47. Global Neisseria meningitidis Infections Drug Sales by Region (2027-2032) & (W Units) Table 48. Global Neisseria meningitidis Infections Drug Sales Market Share by Region (2027-2032) Table 49. Global Neisseria meningitidis Infections Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Neisseria meningitidis Infections Drug Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Neisseria meningitidis Infections Drug Sales Value Share by Region (2021-2026) Table 52. Global Neisseria meningitidis Infections Drug Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Neisseria meningitidis Infections Drug Sales Value Share by Region (2027-2032) Table 54. Global Neisseria meningitidis Infections Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Neisseria meningitidis Infections Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Neisseria meningitidis Infections Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 57. Global Neisseria meningitidis Infections Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Neisseria meningitidis Infections Drug Sales by Country (2021-2026) & (W Units) Table 59. Global Neisseria meningitidis Infections Drug Sales Market Share by Country (2021-2026) Table 60. Global Neisseria meningitidis Infections Drug Sales by Country (2027-2032) & (W Units) Table 61. Global Neisseria meningitidis Infections Drug Sales Market Share by Country (2027-2032) Table 62. Global Neisseria meningitidis Infections Drug Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Neisseria meningitidis Infections Drug Sales Value Market Share by Country (2021-2026) Table 64. Global Neisseria meningitidis Infections Drug Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Neisseria meningitidis Infections Drug Sales Value Market Share by Country (2027-2032) Table 66. Biological E Ltd Company Information Table 67. Biological E Ltd Business Overview Table 68. Biological E Ltd Neisseria meningitidis Infections Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Biological E Ltd Neisseria meningitidis Infections Drug Product Portfolio Table 70. Biological E Ltd Recent Development Table 71. Griffith University Company Information Table 72. Griffith University Business Overview Table 73. Griffith University Neisseria meningitidis Infections Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Griffith University Neisseria meningitidis Infections Drug Product Portfolio Table 75. Griffith University Recent Development Table 76. ImmunoBiology Ltd Company Information Table 77. ImmunoBiology Ltd Business Overview Table 78. ImmunoBiology Ltd Neisseria meningitidis Infections Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. ImmunoBiology Ltd Neisseria meningitidis Infections Drug Product Portfolio Table 80. ImmunoBiology Ltd Recent Development Table 81. JN-International Medical Corp Company Information Table 82. JN-International Medical Corp Business Overview Table 83. JN-International Medical Corp Neisseria meningitidis Infections Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. JN-International Medical Corp Neisseria meningitidis Infections Drug Product Portfolio Table 85. JN-International Medical Corp Recent Development Table 86. MGB Biopharma Ltd Company Information Table 87. MGB Biopharma Ltd Business Overview Table 88. MGB Biopharma Ltd Neisseria meningitidis Infections Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. MGB Biopharma Ltd Neisseria meningitidis Infections Drug Product Portfolio Table 90. MGB Biopharma Ltd Recent Development Table 91. Panacea Biotec Ltd Company Information Table 92. Panacea Biotec Ltd Business Overview Table 93. Panacea Biotec Ltd Neisseria meningitidis Infections Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Panacea Biotec Ltd Neisseria meningitidis Infections Drug Product Portfolio Table 95. Panacea Biotec Ltd Recent Development Table 96. Sanofi Pasteur SA Company Information Table 97. Sanofi Pasteur SA Business Overview Table 98. Sanofi Pasteur SA Neisseria meningitidis Infections Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Sanofi Pasteur SA Neisseria meningitidis Infections Drug Product Portfolio Table 100. Sanofi Pasteur SA Recent Development Table 101. Serum Institute of India Ltd Company Information Table 102. Serum Institute of India Ltd Business Overview Table 103. Serum Institute of India Ltd Neisseria meningitidis Infections Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Serum Institute of India Ltd Neisseria meningitidis Infections Drug Product Portfolio Table 105. Serum Institute of India Ltd Recent Development Table 106. Wellstat Vaccines LLC Company Information Table 107. Wellstat Vaccines LLC Business Overview Table 108. Wellstat Vaccines LLC Neisseria meningitidis Infections Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Wellstat Vaccines LLC Neisseria meningitidis Infections Drug Product Portfolio Table 110. Wellstat Vaccines LLC Recent Development Table 111. Beijing Minhai Biotechnology Co Ltd Company Information Table 112. Beijing Minhai Biotechnology Co Ltd Business Overview Table 113. Beijing Minhai Biotechnology Co Ltd Neisseria meningitidis Infections Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Beijing Minhai Biotechnology Co Ltd Neisseria meningitidis Infections Drug Product Portfolio Table 115. Beijing Minhai Biotechnology Co Ltd Recent Development Table 116. GlaxoSmithKline Plc Company Information Table 117. GlaxoSmithKline Plc Business Overview Table 118. GlaxoSmithKline Plc Neisseria meningitidis Infections Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. GlaxoSmithKline Plc Neisseria meningitidis Infections Drug Product Portfolio Table 120. GlaxoSmithKline Plc Recent Development Table 121. China National Pharmaceutical Group Corp Company Information Table 122. China National Pharmaceutical Group Corp Business Overview Table 123. China National Pharmaceutical Group Corp Neisseria meningitidis Infections Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. China National Pharmaceutical Group Corp Neisseria meningitidis Infections Drug Product Portfolio Table 125. China National Pharmaceutical Group Corp Recent Development Table 126. Pfizer Inc Company Information Table 127. Pfizer Inc Business Overview Table 128. Pfizer Inc Neisseria meningitidis Infections Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Pfizer Inc Neisseria meningitidis Infections Drug Product Portfolio Table 130. Pfizer Inc Recent Development Table 131. Key Raw Materials Table 132. Raw Materials Key Suppliers Table 133. Neisseria meningitidis Infections Drug Distributors List Table 134. Neisseria meningitidis Infections Drug Customers List Table 135. Research Programs/Design for This Report Table 136. Authors List of This Report Table 137. Secondary Sources Table 138. Primary Sources List of Figures Figure 1. Neisseria meningitidis Infections Drug Product Image Figure 2. Global Neisseria meningitidis Infections Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neisseria meningitidis Infections Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Neisseria meningitidis Infections Drug Sales (2021-2032) & (W Units) Figure 5. Global Neisseria meningitidis Infections Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Neisseria meningitidis Infections Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. TP-10 Image Figure 10. NCL-195 Image Figure 11. MGBBP-3 Image Figure 12. Others Image Figure 13. Global Neisseria meningitidis Infections Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 14. Global Neisseria meningitidis Infections Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Neisseria meningitidis Infections Drug Sales Volume Share by Type (2021-2032) Figure 16. Global Neisseria meningitidis Infections Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Neisseria meningitidis Infections Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Neisseria meningitidis Infections Drug Sales Value Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Clinic Image Figure 21. Others Image Figure 22. Global Neisseria meningitidis Infections Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 23. Global Neisseria meningitidis Infections Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Neisseria meningitidis Infections Drug Sales Volume Share by Application (2021-2032) Figure 25. Global Neisseria meningitidis Infections Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Neisseria meningitidis Infections Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Neisseria meningitidis Infections Drug Sales Value Share by Application (2021-2032) Figure 28. Global Neisseria meningitidis Infections Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 29. Global Neisseria meningitidis Infections Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Neisseria meningitidis Infections Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Neisseria meningitidis Infections Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Neisseria meningitidis Infections Drug Sales Value (2021-2032) & (US$ Million) Figure 33. North America Neisseria meningitidis Infections Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Neisseria meningitidis Infections Drug Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Neisseria meningitidis Infections Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Neisseria meningitidis Infections Drug Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Neisseria meningitidis Infections Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Neisseria meningitidis Infections Drug Sales Value (2021-2032) & (US$ Million) Figure 39. South America Neisseria meningitidis Infections Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Neisseria meningitidis Infections Drug Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Neisseria meningitidis Infections Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Neisseria meningitidis Infections Drug Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Neisseria meningitidis Infections Drug Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • TP-10
  • NCL-195
  • MGBBP-3
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Biological E Ltd
  • Griffith University
  • ImmunoBiology Ltd
  • JN-International Medical Corp
  • MGB Biopharma Ltd
  • Panacea Biotec Ltd
  • Sanofi Pasteur SA
  • Serum Institute of India Ltd
  • Wellstat Vaccines LLC
  • Beijing Minhai Biotechnology Co Ltd
  • GlaxoSmithKline Plc
  • China National Pharmaceutical Group Corp
  • Pfizer Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Neisseria meningitidis Infections Drug Sales Value (2021-2032)
  4. 1.2.2 Global Neisseria meningitidis Infections Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Neisseria meningitidis Infections Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Neisseria meningitidis Infections Drug Market Dynamics
  1. 2.1 Neisseria meningitidis Infections Drug Industry Trends
  2. 2.2 Neisseria meningitidis Infections Drug Industry Drivers
  3. 2.3 Neisseria meningitidis Infections Drug Industry Opportunities and Challenges
  4. 2.4 Neisseria meningitidis Infections Drug Industry Restraints
3 Neisseria meningitidis Infections Drug Market by Company
  1. 3.1 Global Neisseria meningitidis Infections Drug Company Revenue Ranking in 2025
  2. 3.2 Global Neisseria meningitidis Infections Drug Revenue by Company (2021-2026)
  3. 3.3 Global Neisseria meningitidis Infections Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Neisseria meningitidis Infections Drug Average Price by Company (2021-2026)
  5. 3.5 Global Neisseria meningitidis Infections Drug Company Ranking (2024-2026)
  6. 3.6 Global Neisseria meningitidis Infections Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Neisseria meningitidis Infections Drug Company Product Type and Application
  8. 3.8 Global Neisseria meningitidis Infections Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Neisseria meningitidis Infections Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Neisseria meningitidis Infections Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Neisseria meningitidis Infections Drug Market by Type
  1. 4.1 Neisseria meningitidis Infections Drug Type Introduction
  2. 4.1.1 TP-10
  3. 4.1.2 NCL-195
  4. 4.1.3 MGBBP-3
  5. 4.1.4 Others
  6. 4.2 Global Neisseria meningitidis Infections Drug Sales Volume by Type
  7. 4.2.1 Global Neisseria meningitidis Infections Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Neisseria meningitidis Infections Drug Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Neisseria meningitidis Infections Drug Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Neisseria meningitidis Infections Drug Sales Value by Type
  11. 4.3.1 Global Neisseria meningitidis Infections Drug Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Neisseria meningitidis Infections Drug Sales Value by Type (2021-2032)
  13. 4.3.3 Global Neisseria meningitidis Infections Drug Sales Value Share by Type (2021-2032)
5 Neisseria meningitidis Infections Drug Market by Application
  1. 5.1 Neisseria meningitidis Infections Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Neisseria meningitidis Infections Drug Sales Volume by Application
  6. 5.2.1 Global Neisseria meningitidis Infections Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Neisseria meningitidis Infections Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Neisseria meningitidis Infections Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Neisseria meningitidis Infections Drug Sales Value by Application
  10. 5.3.1 Global Neisseria meningitidis Infections Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Neisseria meningitidis Infections Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Neisseria meningitidis Infections Drug Sales Value Share by Application (2021-2032)
6 Neisseria meningitidis Infections Drug Regional Sales and Value Analysis
  1. 6.1 Global Neisseria meningitidis Infections Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neisseria meningitidis Infections Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Neisseria meningitidis Infections Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Neisseria meningitidis Infections Drug Sales by Region (2027-2032)
  5. 6.3 Global Neisseria meningitidis Infections Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Neisseria meningitidis Infections Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Neisseria meningitidis Infections Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Neisseria meningitidis Infections Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Neisseria meningitidis Infections Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Neisseria meningitidis Infections Drug Sales Value (2021-2032)
  12. 6.6.2 North America Neisseria meningitidis Infections Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Neisseria meningitidis Infections Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Neisseria meningitidis Infections Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Neisseria meningitidis Infections Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Neisseria meningitidis Infections Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Neisseria meningitidis Infections Drug Sales Value (2021-2032)
  21. 6.9.2 South America Neisseria meningitidis Infections Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Neisseria meningitidis Infections Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Neisseria meningitidis Infections Drug Sales Value Share by Country, 2025 VS 2032
7 Neisseria meningitidis Infections Drug Country-level Sales and Value Analysis
  1. 7.1 Global Neisseria meningitidis Infections Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Neisseria meningitidis Infections Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Neisseria meningitidis Infections Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Neisseria meningitidis Infections Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Neisseria meningitidis Infections Drug Sales by Country (2027-2032)
  6. 7.4 Global Neisseria meningitidis Infections Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Neisseria meningitidis Infections Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Neisseria meningitidis Infections Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Neisseria meningitidis Infections Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Neisseria meningitidis Infections Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Neisseria meningitidis Infections Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Biological E Ltd
  2. 8.1.1 Biological E Ltd Company Information
  3. 8.1.2 Biological E Ltd Business Overview
  4. 8.1.3 Biological E Ltd Neisseria meningitidis Infections Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Biological E Ltd Neisseria meningitidis Infections Drug Product Portfolio
  6. 8.1.5 Biological E Ltd Recent Developments
  7. 8.2 Griffith University
  8. 8.2.1 Griffith University Company Information
  9. 8.2.2 Griffith University Business Overview
  10. 8.2.3 Griffith University Neisseria meningitidis Infections Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Griffith University Neisseria meningitidis Infections Drug Product Portfolio
  12. 8.2.5 Griffith University Recent Developments
  13. 8.3 ImmunoBiology Ltd
  14. 8.3.1 ImmunoBiology Ltd Company Information
  15. 8.3.2 ImmunoBiology Ltd Business Overview
  16. 8.3.3 ImmunoBiology Ltd Neisseria meningitidis Infections Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 ImmunoBiology Ltd Neisseria meningitidis Infections Drug Product Portfolio
  18. 8.3.5 ImmunoBiology Ltd Recent Developments
  19. 8.4 JN-International Medical Corp
  20. 8.4.1 JN-International Medical Corp Company Information
  21. 8.4.2 JN-International Medical Corp Business Overview
  22. 8.4.3 JN-International Medical Corp Neisseria meningitidis Infections Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 JN-International Medical Corp Neisseria meningitidis Infections Drug Product Portfolio
  24. 8.4.5 JN-International Medical Corp Recent Developments
  25. 8.5 MGB Biopharma Ltd
  26. 8.5.1 MGB Biopharma Ltd Company Information
  27. 8.5.2 MGB Biopharma Ltd Business Overview
  28. 8.5.3 MGB Biopharma Ltd Neisseria meningitidis Infections Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 MGB Biopharma Ltd Neisseria meningitidis Infections Drug Product Portfolio
  30. 8.5.5 MGB Biopharma Ltd Recent Developments
  31. 8.6 Panacea Biotec Ltd
  32. 8.6.1 Panacea Biotec Ltd Company Information
  33. 8.6.2 Panacea Biotec Ltd Business Overview
  34. 8.6.3 Panacea Biotec Ltd Neisseria meningitidis Infections Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Panacea Biotec Ltd Neisseria meningitidis Infections Drug Product Portfolio
  36. 8.6.5 Panacea Biotec Ltd Recent Developments
  37. 8.7 Sanofi Pasteur SA
  38. 8.7.1 Sanofi Pasteur SA Company Information
  39. 8.7.2 Sanofi Pasteur SA Business Overview
  40. 8.7.3 Sanofi Pasteur SA Neisseria meningitidis Infections Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Sanofi Pasteur SA Neisseria meningitidis Infections Drug Product Portfolio
  42. 8.7.5 Sanofi Pasteur SA Recent Developments
  43. 8.8 Serum Institute of India Ltd
  44. 8.8.1 Serum Institute of India Ltd Company Information
  45. 8.8.2 Serum Institute of India Ltd Business Overview
  46. 8.8.3 Serum Institute of India Ltd Neisseria meningitidis Infections Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Serum Institute of India Ltd Neisseria meningitidis Infections Drug Product Portfolio
  48. 8.8.5 Serum Institute of India Ltd Recent Developments
  49. 8.9 Wellstat Vaccines LLC
  50. 8.9.1 Wellstat Vaccines LLC Company Information
  51. 8.9.2 Wellstat Vaccines LLC Business Overview
  52. 8.9.3 Wellstat Vaccines LLC Neisseria meningitidis Infections Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Wellstat Vaccines LLC Neisseria meningitidis Infections Drug Product Portfolio
  54. 8.9.5 Wellstat Vaccines LLC Recent Developments
  55. 8.10 Beijing Minhai Biotechnology Co Ltd
  56. 8.10.1 Beijing Minhai Biotechnology Co Ltd Company Information
  57. 8.10.2 Beijing Minhai Biotechnology Co Ltd Business Overview
  58. 8.10.3 Beijing Minhai Biotechnology Co Ltd Neisseria meningitidis Infections Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Beijing Minhai Biotechnology Co Ltd Neisseria meningitidis Infections Drug Product Portfolio
  60. 8.10.5 Beijing Minhai Biotechnology Co Ltd Recent Developments
  61. 8.11 GlaxoSmithKline Plc
  62. 8.11.1 GlaxoSmithKline Plc Company Information
  63. 8.11.2 GlaxoSmithKline Plc Business Overview
  64. 8.11.3 GlaxoSmithKline Plc Neisseria meningitidis Infections Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 GlaxoSmithKline Plc Neisseria meningitidis Infections Drug Product Portfolio
  66. 8.11.5 GlaxoSmithKline Plc Recent Developments
  67. 8.12 China National Pharmaceutical Group Corp
  68. 8.12.1 China National Pharmaceutical Group Corp Company Information
  69. 8.12.2 China National Pharmaceutical Group Corp Business Overview
  70. 8.12.3 China National Pharmaceutical Group Corp Neisseria meningitidis Infections Drug Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 China National Pharmaceutical Group Corp Neisseria meningitidis Infections Drug Product Portfolio
  72. 8.12.5 China National Pharmaceutical Group Corp Recent Developments
  73. 8.13 Pfizer Inc
  74. 8.13.1 Pfizer Inc Company Information
  75. 8.13.2 Pfizer Inc Business Overview
  76. 8.13.3 Pfizer Inc Neisseria meningitidis Infections Drug Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Pfizer Inc Neisseria meningitidis Infections Drug Product Portfolio
  78. 8.13.5 Pfizer Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Neisseria meningitidis Infections Drug Value Chain Analysis
  2. 9.1.1 Neisseria meningitidis Infections Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Neisseria meningitidis Infections Drug Sales Mode & Process
  6. 9.2 Neisseria meningitidis Infections Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Neisseria meningitidis Infections Drug Distributors
  9. 9.2.3 Neisseria meningitidis Infections Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst